Industries > Pharma > Immuno-Oncology Clinical Trials Market Report 2023-2033

Immuno-Oncology Clinical Trials Market Report 2023-2033

Forecasts by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials, Expanded Access Trials), by Indication (Solid Tumours, Hematological Cancer) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

PUBLISHED: 11 September 2023
PAGES: 249
PRODUCT CODE: PHA1282
SUBMARKET: Contract Services

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1282 Categories: , Tags: , ,

The Immuno-Oncology Clinical Trials Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to understand the industry and its underlying dynamics better. It will be useful for companies that want to expand into different industries or their existing operations in a new region.

Increasing Number of Interventional Immuno Oncology Clinical Trials Driving Market Growth
Clinical studies that evaluate a new intervention, like a medicine or a medical technology, are known as interventional trials. Clinical trials in immuno oncology evaluate the efficacy of brand-new immunotherapies for cancer. Furthermore, interventional radiologists have created new procedures and equipment for both intratumor ablative techniques to cure disease and a variety of transarterial intrahepatic therapeutic alternatives, continually improving patient results. Interventional radiologists undertake treatments that can result in immune augmentation, strengthening the role of immunotherapies, such as ablative (radiofrequency and microwave ablation) or embolic.

The number of interventional immuno oncology clinical trials was over 7,000 as of January 2023. More than 3,000 of these trials fell under Phase III. Melanoma, NSCLC, and colorectal cancer are the cancer types that are examined in immuno oncology clinical trials the most frequently. Checkpoint inhibitors, CAR T cells, and oncolytic viruses are the immunotherapies most frequently investigated in immuno oncology clinical trials.

Serious Issues and Substantial Medical Costs Likely to Challenge Industry Growth
Immunotherapy is a relatively recent type of cancer treatment using the body’s immune system to combat cancer cells. Although it is expensive, it has shown significant potential in treating several tumors. There are a few factors that contribute to immunotherapy’s high cost. It is a complicated treatment that necessitates much research and development. Second, it is frequently produced using pricey biologic medications that are challenging to produce. Third, immunotherapy is in high demand, which raises the cost. Many cancer patients may find it difficult to get immunotherapy due to its high cost. Immunotherapy, for instance, typically costs more than $100,000 a year in the United States.

Further, high medical costs are a big issue for patients worldwide. There is intense pressure to reduce costs and demonstrate value. The lack of accessible drugs has impacted population health in underdeveloped nations and shortened average life expectancy. Immunotherapy often involves an average annual cost of above $100,000 per patient; if the worth of medical insurance were considered, this cost would rise to $850,000 per patient. As a result of the high price of immuno oncology therapy, it is projected that the market for immuno oncology medications will expand slowly.

What Questions Should You Ask Before Buying a Market Research Report?
• How is immuno oncology clinical trials market evolving?
• What is driving and restraining immuno oncology clinical trials market?
• How will each immuno oncology clinical trials submarket segment grow over the forecast period, and how much revenue will these submarkets account for in 2033?
• How will the market shares for each immuno oncology clinical trials submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading immuno oncology clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033, and which geographical region will lead the market in 2033?
• Who are the leading players, and what are their prospects over the forecast period?
• What are the immuno oncology clinical trials projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of immuno oncology clinical trials projects taking place now and over the next 10 years?
• Is there a greater need for product commercialization to further scale immuno oncology clinical trials market?
• Where is the immuno oncology clinical trials market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Immuno Oncology Clinical Trials market today, and over the next 10 years:
• Our 249-page report provides 96 tables and 145 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the immuno oncology clinical trials market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Immuno Oncology Clinical Trials prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Phase
• Phase I
• Phase II
• Phase III
• Phase IV

Design
• Interventional Trials
• Observational Trials
• Expanded Access Trials

Indication
• Solid Tumours
• Hematological Cancer

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

Immuno-Oncology Clinical Trials Market Report 2023-2033
Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the Immuno Oncology Clinical Trials Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading Companies and the Potential for market growth
• AstraZeneca plc
• BioNTech SE
• Bristol-Myers Squibb Company
• Exscientia plc
• F. Hoffmann-La Roche AG
• ICON plc
• IO Biotech, Inc.
• IQVIA Inc.
• Medpace, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Syneos Health

Overall world revenue for Immuno Oncology Clinical Trials Market, 2023 to 2033 in terms of value the market will surpass US$6,800 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Immuno Oncology Clinical Trials Market, 2023 to 2033 report help you?
In summary, our 240+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Immuno Oncology Clinical Trials Market 2023 to 2033, with forecasts for phase, design, and indication, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 20 key national markets – See forecasts for the Immuno Oncology Clinical Trials Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, and F. Hoffmann-La Roche AG among others involved in the Immuno Oncology Clinical Trials Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Immuno Oncology Clinical Trials Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Immuno-Oncology Clinical Trials Market Report 2023-2033: Forecasts by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials, Expanded Access Trials), by Indication (Solid Tumours, Hematological Cancer) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Immuno-Oncology Clinical Trials Market Report 2023-2033

    Download sample pages

    Complete the form below to download your free sample pages for Immuno-Oncology Clinical Trials Market Report 2023-2033

      Latest Pharma news

      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ

      Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

      The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

      11 April 2024

      READ

      Visiongain Publishes Female Health Tech Market Report 2024-2034

      The global Female Health Tech market was estimated to be valued at US$ 140.9 billion in 2034 and is expected to register a CAGR of 9.6% from 2024 to 2034.

      05 April 2024

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2024-2034

      The global Meningococcal Vaccines market is projected to grow at a CAGR of 2.5% by 2034

      26 March 2024

      READ